[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,43,67,90,116,140,168,195,216,244,278,296,316,338,358,381,409,430,457,483,505,526,546,575,595],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053612","phase-4-modifying-progesterone-and-estradiol-levels-to-prevent-postpartum-cigarette-smoking-relapse-and-reduce-secondhand-smoke-exposure-in-infants-and-children-100053612",false,"NCT04783857","Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children","Inclusion Criteria:\n\n* Ability to provide informed consent,\n* Aged 18 to 45 years old\n* Self-reported stable physical and mental health\n\n  1. self-report uncomplicated pregnancy at gestational week 30 or beyond, or\n  2. self-report the birth of a child within the past 6 months\n* History of ≥ 4 cigarettes per month during the six months prior to pregnancy\n* At enrollment, self-report of motivation to become and\u002For remain abstinent after delivery ≥ 6 on a 10 point Likert-type scale\n* Willingness to protect against pregnancy following day 0 to week 12 of the study\n* Participants must live in the continental US and have a device to fully participate in the protocol\n\nExclusion Criteria:\n\n* Current daily use of nicotine replacement therapy or smoking cessation medications, with the exception of e-cigarettes\n* Current major depressive disorder based on the Patient Health Questionnaire-9 (PHQ-9) and the Beck Depression Inventory\n* Contraindication to progesterone treatment (e.g., current use of drugs that may inhibit CYP3A4; current or history of deep vein thrombosis, pulmonary embolus, clotting or bleeding disorder, hypertension, stroke, heart disease, or liver dysfunction or disease; or peanut allergy),\n* Current or within the past 3 months treatment for illicit drug use or alcohol use\n* Any condition or issue that, in the opinion of the clinical team, precludes participation in the trial.","FEMALE","18 Years","45 Years",{"count":20,"type":21},171,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The investigators aim to address the following specific aims:\n\n* Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors.\n* Examine the effects of this maternal smoking intervention on infant health.\n* Examine racial and ethnic differences in intervention outcomes.",[27,28,29],"Smoking","Smoking Cessation","Smoking Reduction","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2022-04-14",{"date":38,"type":21},"2027-06-02",{"name":40,"class":41},"University of Minnesota","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100592256","bayesian-neurobehavioral-phenotyping-from-mechanism-identification-to-personalized-neuromodulation-treatments-r61-phase-100592256","NCT06991062","Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHASE","Inclusion Criteria:\n\n1. Age 21 to 60 years\n2. Report smoking on average, 5 or more cigarettes, little cigars and\u002For cigarillos per day, within the past 30 days preceding the screening visit.\n3. Expired carbon monoxide (CO) ≥ 6ppm and\u002For test positive for cotinine using a urine cotinine test on day of study visit.\n4. Able to follow verbal and written instructions in English and complete all aspects of the study.\n5. Have an address and telephone number where they may be reached.\n6. Subjects must report current stable residence. Stable residence is a domicile in which an individual can operate as if it were their own homestead and does not include shelters, halfway houses, treatment centers, or group homes.\n7. Meet safety criteria for EEG.\n8. Be willing to vape from an e-cigarette during specified tasks.\n9. Meet safety criteria for rTMS. Note that if a participant is not eligible for rTMS but is eligible for EEG, they may complete the EEG portion of the study.\n10. Willing and able to independently remove any metal from the neck and above for rTMS procedures (e.g., jewelry)\n11. Provides written informed consent and agree to all assessments and study procedures.\n12. Agrees to complete telehealth (live audio-video conference and\u002For phone) and in-person visits and to be contacted via text.\n\n    Exclusion Criteria:\n13. rTMS exposure for treatment or research purposes in the last 6 months.\n14. History of seizure, epilepsy, syncope, fainting episode, or head trauma resulting in loss of consciousness.\n15. Presence or history of neurological disorders (migraine, stroke, Alzheimer's Disease and other Dementias, Parkinson's Disease, Multiple Sclerosis, Traumatic Brain Injury (TBI), increased intracranial pressure).\n16. History of brain surgery, implanted electronic device, metal in the head.\n17. Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps or sensors, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes)\n18. History of or currently under medical care for myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke, or transient ischemic attack.\n19. Reports vision problems that are not treated.\n20. Has a hairstyle not compatible with the EEG and unwilling to modify hairstyle (e.g., braids, ponytails, dreadlocks, non-removable hair extensions or wigs, etc.) to accommodate the EGG net that is required to be worn on the scalp during the experimental procedure.\n21. Reports current diagnosis or history of type I diabetes.\n22. Currently using insulin.\n23. Have undergone bariatric surgery.\n24. Currently being enrolled in a weight loss program.\n25. Takes any prescription or over the counter medications or supplements to control weight and\u002For appetite.\n26. Self-report a history of or current diagnosis of a mental health condition.\n27. Reports insomnia (\\\u003C4 hours sleep per night, in 3 or more nights per week in the last 3 months)\n28. Reports \\\u003C4 hours of sleep the day of the visit\n29. Reports using marijuana on a daily basis.\n30. Reports having used any other illicit drugs (other than marijuana) or prescription medications for non-medical reasons in the last 12 months.\n31. Currently receiving treatment for substance use disorder (e.g., alcohol, opioids, cocaine, marijuana, or stimulants).\n32. Females who report averaging more than 7 alcoholic drinks, or males who report averaging more than 14 alcoholic drinks in a single week in the last 30 days.\n33. Current use of certain medications (last 3 months):\n\n    Investigational drugs. Drugs of anti or pro-convulsive action. Medications with psychotropic effects (e.g., antidepressants, antipsychotics).\n\n    Medications known to increase risk of seizure Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix). Nicotine replacement therapy with the intent to quit smoking (e.g., patches, gum, lozenge, pouches, etc).\n34. Being pregnant or lactating\n35. Self-reported noise-induced hearing loss or tinnitus.\n36. Currently participating in any other research study.\n37. Any otherwise not specified medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and\u002For Study Physician.\n\n37\\. Any otherwise not specified medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and\u002For Study Physician.\n\n38\\. Subjects considered by the investigator as unsuitable for the study for reasons not otherwise stated.","ALL","21 Years","60 Years",{"count":53,"type":21},100,[55],"NA","The goal of this clinical research study is to learn more about whether individual differences in brain responses to emotional triggers impact rTMS (repetitive transcranial magnetic stimulation) responses in people who smoke.",[27],"2026-06-22",{"date":60,"type":34},"2026-06-23",{"date":62,"type":34},"2025-02-19",{"date":64,"type":21},"2028-12-01",{"name":66,"class":41},"M.D. Anderson Cancer Center",{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100550088","pain-and-smoking-study---interactive-voice-response-100550088","NCT06442514","Pain and Smoking Study - Interactive Voice Response","Enhancing an Intervention for Smokers With Chronic Pain Using IVR: A Randomized Clinical Trial of Smoking Cessation Counseling for Veterans","PASS-IVR","Inclusion Criteria:\n\n* being an enrolled Veteran at VACHS;\n* current tobacco use;\n* willingness to make a quit attempt;\n* significant chronic pain defined as \\>\u002F=4 on the pain intensity portion of the Brief Pain Inventory (BPI) for more than 90 days.\n\nExclusion Criteria:\n\n* active diagnosis of dementia or psychosis in medical record;\n* severely impaired hearing or speech;\n* lack of telephone access;\n* enrollment in concurrent research study that might affect main outcomes of this study;\n* terminal illness;\n* non-English speaking;\n* pregnancy;\n* provider advising against exercise;\n* planned surgeries; and\n* clinically significant depressive symptoms (\\>10 PHQ-9).",{"count":76,"type":21},220,[55],"PASS2 aims to expand upon the recently completed study (PASS intervention), which tested the telephone delivery of a cognitive behavioral intervention (CBI). This study will use Interactive Voice Response (IVR) to optimize the intervention's effectiveness for smoking cessation among Veteran smokers with chronic pain.",[27,80,28],"Pain","NOT_YET_RECRUITING","2026-06-18",{"date":60,"type":34},{"date":33,"type":21},{"date":86,"type":21},"2028-05-31",{"name":88,"class":89},"VA Office of Research and Development","FED",{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":49,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100601259","symptoms-and-functions-in-patients-with-copd-and-chronic-bronchitis-switching-from-cig-to-ths-100601259","NCT07108166","Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS","A Randomized, Single (Operator)-Blinded, Controlled Clinical Study for Assessing Major Symptoms and Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis Who Switch From Combustible Cigarettes (CIG) to Tobacco Heating System (THS)","Inclusion Criteria:\n\n* Adult, both sexes, aged ≥ 40 years.\n* Patient has read, understood, and signed the written informed consent form (ICF), which has received IEC or IRB approval.\n* Patient with body mass index (BMI) 17.6-40.0 kg\u002Fm2 and body weight \\> 50 kg (male) or \\> 40 kg (female). Checked at V1 and V2.\n* Patient has a CIG smoking history ≥ 10 years.\n* Patient has been smoking ≥ 10 commercially available and\u002For roll-your-own CIG\u002Fday on average (no brand restriction) for at least the last year (based on self-reporting). Smoking status will be verified by Urine cotinine test (UCOT) ≥200 ng\u002FmL. Intermittent CIG smoking abstinence, with or without Smoking Cessation Treatment during these attempts, not exceeding 10 days total within the past year will be allowed. Checked at V1 and V2.\n* Patient has been advised to quit smoking, informed of smoking risks and of cessation programs as per SoC at V2, and is not willing to quit CIG use for the study duration. Checked at V1 and V2.\n* Patient agrees to be randomized into one of the two study arms. Checked at V2.\n* Patient with confirmed COPD via spirometry performed at V1 (FEV1\u002FFVC \\\u003C70%, post-bronchodilator (-BD)) and COPD severity classified by the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) as GOLD 2 or 3 (30%≤ FEV1 \\\u003C 80% predicted, -BD) with presence of chronic bronchitis (cough and mucus most of the days for \\> three months a year for the two consecutive years prior to the screening visit). Checked at V2.\n* Patient has cough frequency of ≥ 10 cough\u002Fhour during daytime from objective count sensor applied at V1, used to verify eligibility at V2. (Daytime is defined as occurring between 07:00:00 and 22:59:59, based on the local time zone of the site where the patient is assessed.)\n\nExclusion Criteria:\n\n* Patient who self-report concomitant daily use of inhaled cannabis or any type of nicotine containing products other than CIG within the last year.\n* Patient with COPD (moderate or severe) exacerbation that has not resolved according to the GOLD standard (e.g., requirement of additional therapy) or investigator's discretion. Checked at V1 and V2.\n* Patient with currently active cancer or history of any cancer within the last 5 years prior to V1, except for those with basal cell carcinoma of the skin.\n* Patient with acute worsening symptoms of chronic bronchitis or other active respiratory or systemic infections that have not resolved. Checked at V1 and V2.\n* Patient with medical condition(s) that would jeopardize his(her) safety in the context of this study (e.g., safety laboratory parameters, abnormal ECG) or with a condition that would jeopardize study results (e.g., gastroesophageal reflux disease (GERD), heart failure, severe chronic lung emphysema, active symptomatic hay fever), as per Investigator's discretion. Checked at V1 and V2.\n* Patient is legally incompetent, physically, and\u002For mentally incapable of giving consent (e.g., emergency situation, under guardianship, in a social or sanitary establishment, prisoner or involuntarily incarcerated, unable to read).\n* Patient with a history of asthma.\n* Employee of the investigational site or any other party involved in the study, or their first-degree relatives (parent, child, spouse).\n* Current or former employee of the tobacco or e-cigarette industry or their 1st-degree relatives.\n* Patient with active or history of alcohol and\u002For drug abuse within the past year.\n* Patient with positive serological tests for human immunodeficiency virus (HIV) 1\u002F2, hepatitis B or C (Hep B\u002FC).\n* Patient with any concomitant issues (e.g., medical, psychiatric, and\u002For social reason) that, as per Investigator's discretion, would place the study patient at an unacceptable risk for participation in the study.\n* Patient who participated in any trial (for investigational medicine, or other type of intervention) that may have interfered with COPD disease progression and symptoms (including cough and dyspnea) within the last three months as per investigator's discretion.\n* Patient using any systemic (injectable or oral) corticosteroids (acute or chronic treatments) or oxygen therapy in the last 2 months excluding short term use for a COPD exacerbation.\n* Patient currently being treated with angiotensin-converting enzyme (ACE) inhibitors or opioids, or those who have used ACE inhibitors within 4 weeks or opioids within 1 week prior to screening. Checked at V1 and V2.\n* Patient treated with biologic therapies for COPD (e.g., Dupilumab) in the last 6 months.\n* Female patient is pregnant, breastfeeding or lactating, or anticipating becoming pregnant withing the duration of the study. Checked at V1 and V2.\n* Female of childbearing potential who is capable of getting pregnant, defined as a female patient who does not agree to use an acceptable method of effective contraception during the entire study, a female patient that is not surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year). Checked at V1 and V2.","40 Years",{"count":99,"type":21},290,[55],"The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test \\[6MWT\\]) after switching to THS compared to continuing to smoking cigarettes.",[103,27,104],"COPD","Tobacco Use","2026-06-12",{"date":107,"type":34},"2026-06-15",{"date":109,"type":34},"2025-04-02",{"date":111,"type":21},"2026-11",{"name":113,"class":114},"Philip Morris Products S.A.","INDUSTRY",112,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":49,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100610150","phase-2-a-study-of-brenipatide-in-adults-who-quit-smoking-cigarettes-and-want-to-avoid-relapse-100610150","NCT07223840","A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse","A Phase 2, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for Reduction in Risk of Relapse to Cigarette Smoking in Adults (RENEW-Smk-1)","RENEW-Smk-1","Inclusion Criteria:\n\n* Have recently quit smoking and are motivated to stay quit from smoking\n* Are reliable and willing to make themselves available for the duration of the study and attend required study visits and are willing and able to follow study procedures as required, such as self-inject study intervention\n\nExclusion Criteria:\n\n* Have evidence of any substance use disorder within the past 180 days prior to screening, except mild alcohol use disorder, mild cannabis use disorder, or tobacco use disorder\n* Have answered \"yes\" to either Question 4 or Question 5 on the \"Suicidal Ideation\" portion of the C-SSRS and the ideation occurred within the past 6 months, or have answered \"yes\" to any of the suicide-related behaviors on the \"Suicidal Behavior\" portion of the C-SSRS and the behavior occurred within the past 6 months\n* Have severe chronic obstructive pulmonary disease, or any other clinically severe respiratory condition that in the investigator's opinion may pose a risk.\n* Have participated in a clinical study and have received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening","75 Years",{"count":126,"type":21},222,[128],"PHASE2","This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit.\n\nStudy participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period.",[27],"2026-06-10",{"date":105,"type":34},{"date":134,"type":34},"2025-11-03",{"date":136,"type":21},"2027-02",{"name":138,"class":114},"Eli Lilly and Company",27,{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":42},"100632999","functional-capacity-subjective-dyspnea-and-fatigue-in-smokers-100632999","NCT07520981","Functional Capacity, Subjective Dyspnea and Fatigue in Smokers","Relationship Between Functional Capacity and Subjective Dyspnea and Fatigue in Young Adult Smokers","Inclusion Criteria:\n\n* Being between 18 and 30 years of age.\n* Being actively enrolled in university.\n* Being a current smoker,\n* Having been a regular smoker for at least the last 6 months,\n* Having a daily cigarette consumption of ≥1 cigarette\u002Fday.\n* Volunteering to participate in the study and providing written informed consent.\n* Having the cognitive and physical capacity to understand and complete the tests to be administered.\n\nExclusion Criteria:\n\n* Having a diagnosed chronic respiratory disease (asthma, COPD, bronchiectasis, interstitial lung disease, etc.),\n* Having had an upper or lower respiratory tract infection within the last 4 weeks. Having a diagnosed heart disease (coronary artery disease, heart failure, arrhythmia, etc.),\n* Having a history of uncontrolled hypertension.\n* Having orthopedic problems affecting walking, sitting\u002Fstanding, or balance,\n* Having a history of lower extremity surgery or serious injury within the last 6 months.\n* Having a history of neurological disease affecting balance, coordination, or motor control (stroke, multiple sclerosis, epilepsy, etc.).\n* Having a systemic disease that may prevent participation in exercise (uncontrolled diabetes, severe anemia, etc.),\n* Being pregnant or within the first 6 months postpartum.\n* Having conditions that may endanger the participant's safety during functional tests, o Refusal to complete the tests or inability to cooperate during the evaluation.",true,"30 Years",{"count":150,"type":21},107,"OBSERVATIONAL","Smoking remains a significant public health problem among the young adult population. Epidemiological studies in Turkey show a steadily decreasing age of smoking initiation and a remarkably high rate of smoking among university-aged individuals. Exposure to secondhand smoke is known to have negative effects on the respiratory system, cardiovascular system, and peripheral muscle function.\n\nImpaired lung ventilation, reduced gas exchange, and insufficient oxygen transport due to smoking can lead to decreased exercise tolerance, premature fatigue, and increased perception of exertional dyspnea. These effects can manifest as a decrease in functional capacity even before the development of a clinically significant respiratory disease.\n\nFunctional capacity is an important indicator reflecting an individual's ability to perform daily living activities and is frequently assessed in clinical research using submaximal exercise tests. The 6-Minute Walk Test is a widely used, valid, and reliable test for assessing cardiorespiratory endurance and overall functional status. Similarly, the 1-Minute Sit-Stand Test is recommended as a practical and applicable method for evaluating lower extremity muscle endurance and functional performance.\n\nDyspnea is a multidimensional symptom reflecting an individual's subjective perception of respiratory discomfort and is assessed using scales such as the Modified Medical Research Council and the Borg Dyspnea Scale. The Turkish Thoracic Society's dyspnea assessment reports indicate that exertional dyspnea may increase in smokers even if respiratory function tests are within normal limits.\n\nFatigue, on the other hand, is a significant symptom that negatively affects an individual's daily living activities and physical functionality, arising from inflammatory processes, impaired oxygenation, and decreased physical activity levels associated with smoking. The Fatigue Severity Scale is a validated and reliable scale for assessing the impact of fatigue on an individual's physical and social life.\n\nWhile studies in the literature examine the effects of smoking on respiratory function and exercise capacity, studies that address the relationship between functional capacity and subjective dyspnea and fatigue in young adult smokers are limited. In particular, evaluating functional test results such as the 6-Minute Walk Test and the 1-Minute Sit-Stand Test together with dyspnea and fatigue perception will contribute to the early identification of subclinical functional effects.\n\nThe aim of this study is to examine the relationships between functional capacity (6-Minute Walk Test, 1-Minute Sit-Stand Test, and Timed Up and Go Test) and subjective dyspnea (Modified Medical Research Council Scale - mMRC) and fatigue level (Fatigue Severity Scale) in young adult smokers aged 18-30 years. The findings of this study are expected to draw attention to the functional effects of smoking in young adults, contribute to the development of preventive health approaches, and facilitate the planning of physiotherapy-based assessment and intervention programs.",[27],[155,156,157,158],"functional capacity","subjectice dyspnea","fatigue","young adult smoker","2026-06-07",{"date":161,"type":34},"2026-06-09",{"date":163,"type":34},"2026-04-15",{"date":165,"type":21},"2026-07-30",{"name":167,"class":41},"Istinye University",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":147,"sex":49,"minAge":50,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100638499","a-study-to-determine-the-effects-of-ends-flavor-availability-on-abstinence-within-smokers-100638499","NCT07598136","A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers","A Randomized Controlled Trial to Determine the Effect of Flavor Availability on Smoking Abstinence With an Electronic Nicotine Delivery System in Primary Combustible Cigarette Smokers","Inclusion Criteria:\n\n* Able to read, understand, and are willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.\n* Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent.\n* All female (assigned at birth) and those who identify as \"intersex\" or \"unknown candidate\" participants who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.\n* Currently smoke at least 5 CC on smoking days in the past 30 days.\n* Smoke CC on 15 or more of the past 30 days.\n* Smoked at least 100 factory-made CC in their lifetime prior to the SEV.\n* Indicate a willingness to use ENDS.\n* Own and regularly use a smartphone (iOS or Android) with internet access to download a study application to access surveys and the capability to receive notifications.\n* Agree to participate in the study and to abide by the study restrictions and requirements, as described in the ICF.\n\nExclusion Criteria:\n\n* Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.\n* Male participants who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or refrain from donating sperm from the signing of the ICF until the end of the study, unless they have undergone a vasectomy or are abstinent from heterosexual intercourse, or their female partner was not able to bear children.\n* Female participants who self-report not using adequate methods to prevent pregnancy.\n* Persons with pacemakers or other embedded electronic medical devices fitted.\n* Participants who self-report having an unstable heart condition, severe hypertension or diabetes.\n* Persons who self-report they are allergic\u002Fsensitive to cosmetics or fragrances, or any ingredient listed in commercial e-cigarette products.\n* Participants who self-report poor physical or mental health.\n* Participants who have used ENDS, nicotine pouch, smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products, heated tobacco products, other combustible products and other oral nicotine products (tablets, gums and lozenges) on 5 or more days in the past 30 days.\n* Participants who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.\n* Participants who do not own a smartphone that meets the minimum technical requirements to run the survey app.\n* Employee of a company that manufactures tobacco or ENDS products.\n* Persons who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or ENDS products.\n* Have taken part in a tobacco\u002Fnicotine research study in the past 30 days.","65 Years",{"count":177,"type":21},1280,[55],"The overall purpose of this study will be to assess primary combustible cigarette users' abstinence from smoking their usual brand of combustible cigarettes at the end of the study, when provided with an electronic nicotine delivery system (ENDS) power unit (2) and varying levels of access to tobacco-flavored, menthol-flavored, mint, or non-tobacco\u002Fnon-menthol\u002Fnon-mint-flavored cartridge-based e-liquids (collectively referred to as the investigational product) within their assigned study arm over a three-month (ninety-day) period.",[27,181],"Tobacco",[183,27,104,184],"Tobacco Harm Reduction","Tobacco Smoking","2026-06-01",{"date":187,"type":34},"2026-06-03",{"date":189,"type":34},"2026-05-14",{"date":191,"type":21},"2027-01-21",{"name":193,"class":114},"RAI Services Company",7,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":147,"sex":49,"minAge":97,"maxAge":124,"enrollmentInfo":202,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100417986","lung-macrophage-populations-and-functions-in-chronic-obstructive-pulmonary-disease-copd-susceptible-smokers-100417986","NCT04722835","Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers","Pre-COPD Pilot","Inclusion Criteria:\n\n* Ages between 40 to 75 years old.\n* History of at least 20 pack-years of smoking.\n* No diagnosis of COPD or asthma.\n* No spirometric evidence of airflow obstruction as determined by FEV1\u002FFVC ratio ≥0.7.\n* FEV1 and FVC \\>lower limit of normal.\n* Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months.\n* Subjects will be divided into two groups by their RV\u002FTLC:\n\nNormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC equal or less than lower limit of normal.\n\nAbnormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC higher than lower limit of normal.\n\nExclusion Criteria:\n\n* Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage.\n* Marijuana use \\>400 joints in lifetime or any within past 6 months.\n* Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level.\n* Pregnant\u002Fbreast feeding.\n* Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy.\n* Liver cirrhosis.\n* History of chronic active Hepatitis B or C.",{"count":203,"type":21},40,"Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.",[206,27,104],"Copd",{"date":208,"type":34},"2026-06-04",{"date":210,"type":34},"2021-03-01",{"date":212,"type":21},"2030-12-31",{"name":214,"class":41},"University of California, San Francisco",3,{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":194},"100576776","reduce-tobacco-use-in-people-living-with-hiv-in-switzerland-100576776","NCT06789692","Reduce Tobacco Use in People Living With HIV in Switzerland","Reduce Tobacco Use in People Living With HIV in Switzerland: A Pragmatic Randomized Trial Within the Swiss HIV Cohort Study","RETUNE","Inclusion Criteria:\n\n* Signed informed consent for the data collection and participation in the SHCS (Cohort consent).\n* Signed informed consent to be randomized to future interventions (Randomization consent).\n* Age 18 years or older.\n* Smoked one or more tobacco cigarettes per day (smoking status = yes) at the time of enrolment.\n\nExclusion Criteria:\n\n* Currently using e-cigarettes or nicotine pouches or nicotine patches.\n* Pregnant women.",{"count":225,"type":21},972,[55],"The purpose of this trial is to test the effectiveness of offering a menu of different tobacco smoking substitutional products (e-cigarettes, nicotine pouches, nicotine patches in addition to usual of care) for smokers in the SHCS (Swiss HIV Cohort Study) in achieving self-reported 7-day tobacco cigarette abstinence at 6 months.",[229,27],"HIV",[231,232,233,234],"tobacco smoking","e-cigarettes","tobacco-free nicotine pouches","Trials within Cohorts (TwiCs)","2026-05-28",{"date":237,"type":34},"2026-06-02",{"date":239,"type":34},"2025-02-20",{"date":241,"type":21},"2027-12",{"name":243,"class":41},"University Hospital, Basel, Switzerland",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":252,"conditions":253,"keywords":259,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":42},"100557265","the-efficacy-of-conventional-screening-versus-mhealth-screening-in-early-detection-of-oral-potentially-malignant-disorders-and-oral-cancer-amongst-the-rural-population-of-varanasi-a-prospective-and-blinded-study-100557265","NCT06535867","The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study","Inclusion Criteria:\n\nPositive for any one or more of the following:\n\n* All individuals aged above 18 years positive for habits (smoking and smokeless tobacco, chewing betel leaf, areca nut, paan masala, and\u002For regular use of alcohol)\n* Clinical signs\u002Fsymptoms (non-healing ulcers, white\u002F red\u002Fred \\& white patches in the mouth, restriction of mouth opening and swelling of the neck)\n* All individuals aged above 40 irrespective of habit\u002Foral lesions\n\nExclusion Criteria:\n\n* Individuals already diagnosed with oral cancer and undergoing treatment for oral cancer\n* Under treatment for tuberculosis or suffering from any acute illness\u002F debilitating systemic disorders",{"count":251,"type":21},5122,"Mobile health (mHealth) will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers. This program is inclusive of long term surveillance to downstage oral cancer in India",[27,254,255,256,104,184,257,258],"Smoking, Cigarette","Smoking, Tobacco","Betel Chewer's Mucosa","Alcohol Drinking","Smokeless Tobacco Hyperkeratosis",[260,261,262,263,264,265,266,267,268,269],"smoking","smoking, cigarette","smoking, tobacco","smokeless tobacco","betel leaf","areca nut","paan masala","alcohol use","Memorial Sloan Kettering Cancer Center","24-148","2026-05-19",{"date":272,"type":34},"2026-05-22",{"date":274,"type":34},"2024-07-30",{"date":276,"type":21},"2031-07-30",{"name":268,"class":41},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":147,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100639243","abuse-liability-of-two-modern-oral-nicotine-pouched-products-100639243","NCT07595055","Abuse Liability of Two Modern Oral Nicotine Pouched Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability of Two Modern Oral Nicotine Pouched Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use ST (e.g., moist snuff).\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.\n5. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n6. Reports daily use of ST products (i.e., moist snuff) and agrees to use the same UB ST throughout the study period. The UB moist snuff is defined as the reported moist snuff brand and style currently used most frequently by the participant.\n7. Expired breath carbon monoxide (eCO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day 1).\n8. Positive urine cotinine test (i.e., ≥200 ng\u002FmL) via dipstick at Screening and at Check-in Day 1.\n9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991) OR response at Screening to \"How soon after you wake up do you place your first dip?\" is either \"Within 5 minutes\" or \"6-30 minutes\" from the Fagerström Test for Nicotine Dependance-Smokeless Tobacco (FTND-ST) (Ebbert et al., 2006).\n10. Willing to use Study IPs, their UB cigarette and UB moist snuff (Study IP Product S) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. abstinence;\n    4. non-hormone releasing intrauterine devices (IUD);\n    5. vasectomized partner; or\n    6. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of five days (four nights).\n14. BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening)\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system or tobacco heating device within the 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day 1.\n10. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n11. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n12. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n13. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n14. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within 30 days prior to signing the informed consent.\n15. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n16. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n17. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n18. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.\n19. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.\n20. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n21. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n22. Drinks more than 21 servings of alcoholic beverages per week.\n23. Determined by an investigator to be inappropriate for this study.",{"count":203,"type":21},[55],"This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.",[27,289,104,184],"Smoking Behaviors","2026-05-12",{"date":270,"type":34},{"date":107,"type":21},{"date":294,"type":21},"2026-11-30",{"name":193,"class":114},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":42},"100599854","phase-4-project-deduce-digital-envirotyping-to-develop-understanding-of-cigarette-smoking-and-the-environment-100599854","NCT07089901","Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment","DEDUCE","Inclusion Criteria:\n\n1. 21 years of age or older;\n2. Smoke ≥ 10 cigarettes\u002Fday of a brand delivering 0.5 mg nicotine (FTC method);\n3. Smoking daily for ≥ 2 years, with a stable smoking pattern for the past 6 months;\n4. Intention to quit smoking and set a target quit date in the next 1 month;\n5. Have an iPhone or Android smartphone capable of running the photoEMA and iCO software\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or planning to become pregnant during the course of the study;\n2. Currently in smoking cessation treatment or current use of smoking cessation products;\n3. Regular use (i.e. \\>9 days\u002Fmonth) of non-cigarette nicotine-containing products (e.g. cigarillos, e-cigarettes);\n4. Anticipating major life changes (e.g. new job, birth of a child) during the course of the study;\n5. Unstable medical conditions;\n6. Contraindication for nicotine replacement therapy.",{"count":304,"type":21},600,[24],"Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, \\>70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to relapse. However, despite this knowledge, understanding of environmental correlates of smoking has been limited by a reliance on self-report, leading to imprecise information about the physical environments in which people live. To overcome this challenge, the research team has pioneered the development of digital envirotyping, which uses digital tools (e.g., sensors, cameras, artificial intelligence) to efficiently and accurately characterize and categorize environments with the goal of identifying environmental markers of behavior and health. Foundational to the digital envirotyping research is computer vision (CV), a type of artificial intelligence (AI) that enables computer systems to recognize objects and scenes in digital images, mimicking how humans perceive and understand visual information. With CV researchers can extract detailed and accurate information (i.e., objects and location types) about the everyday environments of people who smoke (PWS) and relate that information to smoking behavior. After validating the use of CV, the researchers used CV to develop enviromarkers of relapse risk. Importantly, they identified a novel enviromarker in which people at greater risk for relapse when they quit are exposed to a more consistent level of environment-related smoking risk as they move between their smoking and nonsmoking environments.\n\nResearch is now needed to advance digital envirotyping and enviromarker development in the field of tobacco addiction. The study will recruit a diverse, national sample of n=500 adults who are interested in quitting smoking. For two weeks prior to quitting, they will undergo photoEMA in which they will take two pictures of their current environment when they smoke, and randomly 10 times per day resulting in \\>300,000 images total. Cessation will be supported by nicotine replacement therapy (i.e., nicotine patch). The primary clinical outcome will be days to relapse. Specific aims are to (1) further develop, refine, and validate methods for efficient digital envirotyping at scale, (2) leverage CV and AI approaches to develop enviromarkers of smoking relapse, and (3) conduct analyses to increase understanding of environmental smoking risk in women and individuals with low socioeconomic status.",[27],"2026-05-11",{"date":290,"type":34},{"date":311,"type":34},"2026-05-06",{"date":313,"type":21},"2030-03-31",{"name":315,"class":41},"Duke University",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":147,"sex":49,"minAge":50,"maxAge":175,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":42},"100627053","assessment-of-hphc-exposure-in-smokers-switching-to-thstp18-with-different-device-variants-100627053","NCT07443631","Assessment of HPHC Exposure in Smokers Switching to THS\u002FTP18 With Different Device Variants","A Randomized, Controlled, Open-label, 6 Parallel Arms Study to Assess Exposure to Selected Harmful and Potentially Harmful Constituents (HPHC) of Cigarette (CIG) Smoke in Adult Smokers Switching to Tobacco Heating Systems (THS\u002FTP18) With Different Device Variants as Compared to Continuing CIG Smoking","Inclusion Criteria:\n\n* Participant has signed the ICF and understands the information provided in it.\n* Participant is male or female and between 21 and 65 years old (inclusive).\n* Participant has been a smoker for at least 2 years prior to the screening visit and is willing to switch to THS and TP18.\n* Participant has smoked on average ≥10 commercially available CIGs\u002Fday over the last 30 days. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng\u002FmL).\n* Participant does not plan to quit smoking within the next three months.\n* Participant is available for the entire study period and willing to comply with the study procedures, including product use assignments and periods of abstinence from any nicotine\u002Ftobacco-containing products, and willing to adhere to a standardized diet (during confinement period and during overnight stays on Day 30 and Day 60).\n\nExclusion Criteria:\n\n* As per the Investigator's judgment, the participant cannot participate in the study for any reason other than medical (e.g., psychological, social reason).\n* Participant is legally incompetent, or physically or mentally incapable of giving consent (e.g., in emergency situations, under guardianship, prisoners).\n* Participant has a health condition which requires medication or any other clinically relevant finding based on available assessments from the Screening period (e.g., safety panel, pulmonary function test, vital signs, physical examination, ECG, and medical history), as determined by the Principal Investigator or designee.\n* Participant experienced within 30 days prior to screening\u002Fadmission a body temperature \\>37.9°C or an acute illness (e.g., upper respiratory-tract infection, viral infection, etc.).\n* According to the Investigator's judgment, the participant has medical conditions that require or will require medical intervention (e.g., initiation of treatment, surgery, hospitalization) during the study period, which may interfere with study participation and\u002For study results.\n* Participant uses medication that aids in smoking cessation.\n* Participant experiences difficulty with venipuncture and\u002For poor venous access.\n* Participant has a hemoglobin level \\\u003C 11.0 g\u002FdL for females and \\\u003C 12.0 g\u002FdL for males at the Screening visit.\n* Participant has a positive nitrite urinary test at screening or on admission day (Day -2)\n* Participant has donated blood or received whole blood or blood products within the past 3 months.\n* BMI \\\u003C 18.5 kg\u002Fm2 or ≥ 32.0 kg\u002Fm2.\n* Positive serology test for HIV 1\u002F2, HBV, or HCVa.\n* Participant has a positive alcohol breath test and\u002For has a history of alcohol disorder that could interfere with their participation in the study.\n* The participant has a positive urine drug test.\n* Participant or one of their family members is a current or former employee of the tobacco industry, manufacturing or distributing e-cigarettes or other nicotine\u002Ftobacco-containing products.\n* A participant or a family member is an employee of the investigational site or of any other parties involved in the study.\n* Participant has participated in another clinical study within 30 days or within a period equivalent to five half-lives of the investigational product from that study, whichever is longer. .\n* Participant has been previously screened or enrolled in this study (unless they are alternate subjects).\n* Female participant is pregnant (does not have negative pregnancy tests at screening and\u002For at admission) or is breastfeeding.\n* For women of childbearing potential only and males: participant does not agree to use an acceptable method of effective contraception.",{"count":324,"type":21},108,[55],"This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS\u002FTP18 and CIG, and followed by an ambulatory period.",[27],[329],"HPHC","2026-04-30",{"date":332,"type":34},"2026-05-01",{"date":334,"type":34},"2026-02-19",{"date":336,"type":21},"2026-12-18",{"name":113,"class":114},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":147,"sex":49,"minAge":50,"maxAge":175,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":42},"100483256","linking-brain-network-dynamics-to-imminent-smoking-lapse-risk-and-behavior-100483256","NCT05572671","Linking Brain Network Dynamics to Imminent Smoking Lapse Risk and Behavior","Inclusion Criteria:\n\n* Participants must be between the ages of 21 and 65.\n* Participants must be fluent English speakers.\n* Participants must pass an MRI safety screening.\n* Participants must report smoking at least six cigarettes per day continuously for at least the 12 preceding months.\n* Participants must have a baseline expired-air carbon monoxide exceeding 10 parts per million in order to verify smoking status.\n\nExclusion Criteria:\n\n* Individuals will be excluded if they report that they are not willing to refrain from using nicotine for 12 hours before the experimental lab visit.\n* Individuals will be excluded if they have any known risk from exposure to high-field strength magnetic fields (e.g., pacemakers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments that are likely to create artifact on the MRI scans.",{"count":345,"type":21},150,[55],"Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.",[27,104],"2026-04-29",{"date":351,"type":34},"2026-05-05",{"date":353,"type":34},"2023-04-04",{"date":355,"type":21},"2027-08",{"name":357,"class":41},"Penn State University",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":22,"phases":368,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":42},"100451143","phase-3-integrating-financial-coaching-and-smoking-cessation-coaching-100451143","NCT05154669","Integrating Financial Coaching and Smoking Cessation Coaching","Integrating Financial Coaching and Smoking Cessation Coaching for People With Low Income Who Smoke: a Randomized Controlled Trial","Inclusion Criteria:\n\n* age ≥18 years,\n* smokes ≥5 cigarettes per day,\n* interested in receiving smoking and financial counseling,\n* self-reported income below 200% of the current federal poverty level,\n* New York City resident,\n* speaks English or Spanish language (the interventions and measures have not been validated in other languages),\n* able to provide informed consent, and\n* does not have a representative who manages his\u002Fher funds.\n\nExclusion Criteria\n\n* people who know a current past study participant (to avoid intervention contamination)\n* People who have a medical contraindication to using nicotine replacement therapy:\n* allergy to nicotine patch\n* pregnancy or intention to become pregnant over the next 12 months\n* breastfeeding\n* heart attack in the past 2 months\n* underlying arrhythmia\n* ongoing or worsening angina.","100 Years",{"count":367,"type":21},602,[369],"PHASE3","This study conduct a two-arm, parallel-group randomized controlled trial. The study will recruit and randomize 900 smokers (n=450 per arm) to either: (1) Control: Standard Smoking Cessation Counseling or (2) Intervention: Integrated Financial-Smoking Cessation Counseling.",[27],"2026-04-28",{"date":374,"type":34},"2026-05-04",{"date":376,"type":34},"2022-12-08",{"date":378,"type":21},"2029-12-01",{"name":380,"class":41},"NYU Langone Health",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":147,"sex":49,"minAge":388,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":42},"100131538","early-phase-1-the-effect-of-emotional-freedom-techniques-eft-in-smokers-failing-a-smoking-cessation-program-100131538","NCT00981396","The Effect of Emotional Freedom Techniques (EFT) in Smokers Failing a Smoking Cessation Program","The Effect of EFT (Emotional Freedom Techniques) in Smokers Failing a Smoking Cessation Program","Inclusion Criteria:\n\n* High anxiety related to the quit attempt\n* Cravings which sabotage the quit attempt\n* Low confidence at their ability to quit and remain quit\n\nExclusion Criteria:\n\n* None, all NHS clients are eligible","12 Years","99 Years",{"count":203,"type":21},[392],"EARLY_PHASE1","The National Health Service (NHS) stop smoking service at the Central Lancashire NHS Trust serves a diverse population of smokers, with a very good quit rate and high standards. However, clinical experience predicts that some clients are unlikely to succeed through the NHS smoking cessation program. This special population has difficulty quitting for a variety of reasons. Some relapse over the course of the following two years and return repeatedly to the service. Others, for instance those with health problems, may be highly motivated to quit, but unable to resist their cravings. The purpose of this study is to determine if EFT makes a difference in quit rates with the most challenging population of clients.",[27],[260,396,397,398,399],"EFT (Emotional Freedom Techniques)","CBT (cognitive behavior therapy)","cravings","trauma","2026-04-22",{"date":402,"type":34},"2026-04-27",{"date":404,"type":34},"2009-09-20",{"date":406,"type":21},"2027-12-31",{"name":408,"class":41},"Soul Medicine Institute",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":42},"100490007","leveraging-community-pharmacists-to-optimize-smoking-cessation-services-for-rural-smokers-in-appalachia-100490007","NCT05660525","Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia","Study participants will be rural cigarette smokers from Virginia, Tennessee, Kentucky and North Carolina who visit one of the participating study pharmacies. Pharmacies will be located in rural geographic areas of the Central and South Central subregions of Appalachia that include Virginia, Tennessee, Kentucky and North Carolina, as defined by the USDA Rural-Urban Continuum Codes (RUCC) 4-9, Rural-Urban Commuting Area (RUCA) codes 4-10, or Frontier and Remote (FAR) areas level 4. No exclusionary criteria are based on race, gender, or age.\n\nInclusion Criteria include:\n\n* must be 18 years of age and older\n* must be able to read, speak, and understand English\n* must report smoking at least 5 cigarettes per day for the past 6 months (regardless of non-cigarette tobacco product use)\n* must be willing to set a quit date within the next 30 days\n* must own a cell phone\n* must be willing and able to use NRT in the form of patch or lozenge\n* Not be pregnant or planning to be pregnant in the next 6 months.\n\nExclusion Criteria include:\n\n* are pregnant women (self-reported), breastfeeding, planning to become pregnant during the next 6 months\n* have a medical contraindication to NRT (e.g., past 30 days, heart attack or stroke; past 6 months, serious or worsening angina, very rapid or irregular heartbeat requiring medication)",{"count":416,"type":21},768,[55],"The goal of this clinical trial is to evaluate the effectiveness and implementation of a pharmacist-delivered MTM (medication therapy management) approach, called QuitAid, to quitting cigarette smoking in rural Appalachia.\n\nThe main questions it aims to answer are:\n\n* Is QuitAid, alone or combined with other quitting tobacco treatments, effective?\n* What makes QuitAid easy or hard to carry out? Is it cost effective? Is it easy to maintain?\n\nTreatment:\n\nAll participants will be given at least 4 weeks of the nicotine patch.\n\nSome participants will be randomized (like the flip of a coin) to receive additional treatments (listed below).\n\nThese groups will be compared to each other to see which combination works best to help them quit smoking.\n\n* Smokefree TXT - a texting program that helps people quit smoking\n* Tobacco quitline - 4 phone sessions to help people quit smoking\n* 8 weeks of NRT (nicotine replacement therapy in the form of nicotine patches or nicotine patches and lozenge) medication instead of 4 weeks\n* QuitAid - An MTM program given by the patient's pharmacist. This is a quitting smoking coaching program\n* Nicotine patch AND nicotine lozenge instead of just nicotine patches",[28,254,29,27,255,420],"Quitting Smoking","2026-04-16",{"date":423,"type":34},"2026-04-20",{"date":425,"type":34},"2024-03-06",{"date":427,"type":21},"2028-03-01",{"name":429,"class":41},"University of Virginia",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":42},"100542681","phase-4-implementation-of-transcranial-magnetic-stimulation-for-smoking-cessation-100542681","NCT06346028","Implementation of Transcranial Magnetic Stimulation for Smoking Cessation","A Pragmatic Feasibility Trial on the Implementation of Transcranial Magnetic Stimulation for Smoking Cessation","Inclusion Criteria: Patients receiving rTMS\n\n* Smoking cigarettes daily (self-reported)\n\nInclusion Criteria: Health care providers\n\n* Currently employed as a HCP (physician, social worker, occupational therapist, etc.) at the CAMH NDC\n* Involved in the care of at least 1 patient who has received rTMS for smoking cessation\n\nExclusion Criteria: Patients receiving rTMS\n\n* Have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.\n* Pregnant or intending to be pregnant during the study.\n* A history of a primary seizure disorder, seizure associated with an intracranial lesion, recurrent seizures related to substance intoxication or withdrawal or recent seizure within the last 6 months.\n* Taking any anticonvulsant medication unless it cannot be tapered or discontinued due to risk of clinical safety or destabilization, according to the participant or their referring physician.\n* Taking benzodiazepines with dose equivalent or greater than lorazepam 2mg\u002Fday unless it cannot be tapered or discontinued due to risk of clinical safety or destabilization, according to the participant or their referring physician.\n* Space occupying intracranial lesion.\n* Acutely unstable medical, psychiatric, or substance use disorder comorbidity with safety concerns at the discretion of the PI or study physician.\n\nExclusion Criteria: Health care providers\n\n\\- There are no exclusion criteria for HCP Participants","70 Years",{"count":203,"type":21},[24],"Repetitive transcranial magnetic stimulation (rTMS) is an alternative non-invasive treatment to help people quit smoking. rTMS uses a magnetic field to stimulate regions of the brain that are involved in addiction. The two brain regions that are stimulated are the insula and the dorsolateral prefrontal cortex, which are involved in drug craving and decision-making, respectively.\n\nThe goal of this clinical trial is to learn more about the feasibility of offering rTMS as a treatment in the Nicotine Dependence Clinic (NDC) to help daily smokers to quit smoking. The NDC is at the Center for Addiction and Mental Health (CAMH) at 1025 Queen Street West, in Toronto, Canada.\n\nParticipants will be asked to come to CAMH to:\n\n* Complete surveys and optional interviews to learn more about their opinions and experiences with this treatment\n* Start a treatment course that includes 3 weeks of daily (Monday to Friday) rTMS sessions followed by 3 weeks of weekly rTMS sessions for a total of 6 weeks. Each session lasts about 25 minutes and is provided by an rTMS technician with medical supervision.\n\nObjectives\n\n• Learning about the feasibility of rTMS as a treatment option for patients in the NDC will help us improve the treatment when offering it in other clinics, which may help improve smoking quit rates and people's overall health.",[27],[443,444,445,446,447],"smoking cessation","quitting smoking","repetitive transcranial magnetic stimulation","rTMS","nicotine dependence","2026-03-26",{"date":450,"type":34},"2026-03-27",{"date":452,"type":34},"2024-03-30",{"date":454,"type":21},"2028-06-30",{"name":456,"class":41},"Centre for Addiction and Mental Health",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":464,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":42},"100630520","comparison-of-the-effects-of-different-chest-techniques-on-university-students-with-smoking-addiction-100630520","NCT07488741","Comparison of the Effects of Different Chest Techniques on University Students With Smoking Addiction","Comparison of the Effects of Chest PNF Techniques and Chest Mobility Exercises on Respiratory Function, Chest Expansion, and Functional Capacity in University Students With Smoking Addiction: A Single-Blind Randomized Controlled Study","Inclusion Criteria:\n\n* Age of 18-24 years\n* Fagerström Nicotine Dependence Questionnaire score ≥4\n* Smoking for at least 2 years\n* Daily smoking ≥5 cigarettes and at least 90 pack-years. Stable condition (no acute respiratory infection in the last 4 weeks).\n* FEV1 ≥80%\n* Voluntary participation in the study\n* No orthopedic or neurological problems that would prevent participation in exercise\n\nExclusion Criteria:\n\n* Cardiac event or lung surgery in the last 6 months\n* Respiratory problems such as COPD, asthma\n* Orthopedic and neurological problems\n* Termination of volunteering","24 Years",{"count":466,"type":21},30,[55],"Smoking is a significant risk factor for heart, lung, and respiratory system diseases, and is particularly prevalent among young people and university students. In Turkey, tobacco use is high in the 15-24 age group, and smoking rates among university students are reported to be between 20% and 43%. Besides causing COPD and other respiratory diseases, smoking negatively impacts performance by increasing fatigue, dyspnea, and pain during exercise. It impairs lung function, reducing respiratory volumes such as FVC and FEV1. PNF and chest mobility exercises targeting the chest area can improve respiratory parameters by increasing respiratory muscle function and thoracic mobility. Recent studies show that chest PNF techniques have positive effects on lung function, chest expansion, and some physiological parameters, especially in smokers.",[27],[471,472,473],"Smokers","Exercise","Proprioceptive Neuromuscular Facilitation (PNF) Stretching","2026-03-22",{"date":476,"type":34},"2026-03-25",{"date":478,"type":34},"2026-03-09",{"date":480,"type":21},"2026-12-31",{"name":482,"class":41},"University of Yalova",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":42},"100522026","effects-of-e-cigs-vs-pouches-on-cigarette-smoking-and-addiction-100522026","NCT06077240","Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction","Evaluating The Effects Of E-cigarettes Versus Oral Nicotine Pouches and Product Constituents (Menthol Flavor, Nicotine Concentration) On Adult Cigarette Smoking and Addiction","Inclusion Criteria:\n\n* 21+ years old\n* English literate\n* Currently smoking cigarettes, biochemically confirmed\n\nExclusion Criteria:\n\n* Currently using smoking cessation pharmacotherapies (NRT, bupropion, varenicline)\n* Currently pregnant or breastfeeding\n* Significant current medical or psychiatric condition\n* Known hypersensitivity to propylene glycol",{"count":491,"type":21},256,[55],"The study will recruit an anticipated 256 adults who currently smoke cigarettes and report a willingness to try switching to alternative, non-combustible products. Participants will be randomized to receive either e-cigarettes or nicotine pouches for a duration of 4 weeks and to 1 of 4 possible regulatory scenarios within products where flavor availability is either menthol and tobacco\u002Funflavored available or tobacco\u002Funflavored only available, and nicotine concentration is either higher (5% e-cig, 6mg pouch) or lower (2.4% e-cig, 3mg pouch). Participants will return for bi-weekly research visits (in person or remote videocall) to complete measures for study aims. Participants will complete a final follow-up at Week 6 to assess maintenance of cigarette reduction and willingness to continue using products once they are no longer provided. The investigators expect to observe which products and constituents lead to greater smoking reduction.",[27,289,495],"Nicotine Dependence","2026-03-17",{"date":498,"type":34},"2026-03-19",{"date":500,"type":34},"2024-08-20",{"date":502,"type":21},"2028-04-01",{"name":504,"class":41},"Yale University",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":4},"100580625","phase-1-addressing-parental-tobacco-use-in-somali-immigrant-families-adapting-an-evidence-based-intervention-in-primary-care-100580625","NCT06839729","Addressing Parental Tobacco Use in Somali Immigrant Families: Adapting an Evidence-Based Intervention in Primary Care","Addressing Parental Tobacco Use in Somali Immigrant Families: Adapting an Evidence-based Intervention in Pediatric Primary Care","Inclusion Criteria:\n\n* age over 18 years\n* self-reported 1 st or 2 nd generation Somali identity\n* parent or legal guardian at least one pediatric patient within the MHF system\n* self-reported use of combustible cigarettes (even a puff) in the past 30 days\n* access to a telephone\n\nExclusion Criteria:\n\nClinician or staff participant:\n\n* Inability or unwillingness to participate in implementing CEASE+\n* Employees or students of the research team\n\nParent participant:\n\n* Having participated in Aim 1",{"count":513,"type":21},50,[515],"PHASE1","This study will modify an existing evidence-based parental tobacco cessation intervention (the Clinical Effort Against Secondhand Smoke Exposure, or CEASE) delivered in pediatric primary care clinics to address shared tobacco use determinants and barriers to smoking cessation treatment among Somali Americans, an immigrant population facing significant combustible tobacco use disparities.",[27,28],"2026-02-24",{"date":520,"type":34},"2026-02-27",{"date":522,"type":21},"2027-01-01",{"date":524,"type":21},"2029-12-31",{"name":40,"class":41},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":147,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":42},"100536386","the-role-of-flavor-in-the-substitutability-of-e-cigarettes-for-combustible-cigarettes-among-persistent-smokers-100536386","NCT06264154","The Role of Flavor in the Substitutability of E-cigarettes for Combustible Cigarettes Among Persistent Smokers","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e. speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 12 months\n3. 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.\n4. Ever use of an e-cigarette\n5. Have a carbon monoxide (CO) greater than 10 ppm\n6. Not using any forms of nicotine regularly other than cigarettes\n7. Be willing to switch to e-cigarettes for 6 weeks and use the assigned flavors\n8. Plan to live in the area for the duration of the study\n9. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\nSmoking Behavior Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette use is defined as greater than 5 days\u002Fpast 30 days\n\n1. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.\n2. Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.\n3. Current use of smoking cessation medication\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n4. Breath alcohol reading (BrAC) greater than .000 at Intake.\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.\n3. Allergies to either propylene glycol or flavor additives\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator and\u002Fo. Subjects may be deemed ineligible at any point throughout the study.",{"count":533,"type":21},210,[55],"This between-subjects study aims to evaluate the effect of flavor on initial and sustained switching from combustible cigarettes to e-cigarettes among 210 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to a six-week regimen of fruit-flavored, tobacco-flavored, or menthol-flavored e-cigarettes and be instructed to switch (versus smoking cigarettes) over a 6-week period. Flavor-associated subjective reward and the reinforcing value of flavored e-cigarettes relative to combustible cigarettes will be assessed as mechanisms.",[27,104,537,538],"Cigarette Smoking","E-Cig Use","2026-02-17",{"date":334,"type":34},{"date":542,"type":34},"2024-08-26",{"date":241,"type":21},{"name":545,"class":41},"Abramson Cancer Center at Penn Medicine",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":42},"100499994","take-a-break---rural-100499994","NCT05790486","Take A Break - Rural","Using Rural Community Paramedicine to Engage Lower-Motivated Smokers: Spreading an Effective mHealth-Assisted Intervention to Motivate Cessation","TABR","Inclusion Criteria:\n\n* Current Smoker\n* at least 18 years old\n* speaks English\n* Able to receive texts and read text (literate)\n* Have a text-enabled phone or receive one from the study team\n* Not yet ready to quit smoking\n\nExclusion Criteria:\n\n* actively quitting smoking\n* preparing to quit smoking within 30 days\n* prisoners\n* FDA- defined NRT contraindications\n* unable or unwilling to provide informed consent",{"count":555,"type":21},800,[55],"The study team proposes a multi-level trial to test 1) novel implementation programs in rural counties designed to increase access to 2) recent advances in tobacco control services for people who are not-yet-ready-to-quit smoking. In this field, most trials have focused only on those already ready-to-quit. Thus, the proposed trial addresses an important knowledge gap critical to advance tobacco control in rural areas.",[27,289,28],[560,561,562,563,564,565],"smoking rates","public health tobacco control services","smoking cessation service","Rural Health","Implementation Science","Community Paramedicine","2026-02-09",{"date":568,"type":34},"2026-02-11",{"date":570,"type":34},"2023-07-11",{"date":572,"type":21},"2026-12",{"name":574,"class":41},"Wake Forest University Health Sciences",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":147,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":584,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":42},"100522890","phase-2-app-for-reducing-cravings-to-smoke-100522890","NCT06088498","App for Reducing Cravings to Smoke","Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation","Inclusion Criteria:\n\n* \\>18 years of age\n* Daily smokers that have quit smoking within the past 3 months (Aim 1) or currently smoking ≥ 3 cigarettes per day for the past year (Aim 2)\n* Functioning telephone number\n* Owns a smart phone capable of supporting AR and willing to download the app\n* Can speak, read and write in English\n\nExclusion Criteria:\n\n* Has another household member already enrolled in the study",{"count":583,"type":21},3600,[128],"The overall goal of the study is to assess the efficacy of using cue exposure delivered via a smartphone application as an adjunct to Tobacco Quitline treatment to improve smoking abstinence.",[27],"2026-02-05",{"date":566,"type":34},{"date":590,"type":34},"2024-06-11",{"date":592,"type":21},"2027-05-01",{"name":594,"class":41},"H. Lee Moffitt Cancer Center and Research Institute",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":608,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":42},"100504325","personalized-tobacco-treatment-in-primary-care-motivate-100504325","NCT05846841","Personalized Tobacco Treatment in Primary Care (MOTIVATE)","A Multilevel Intervention to Personalize and Improve Tobacco Treatment in Primary Care (MOTIVATE)","Eligibility Criteria for Primary and Specialty Care Clinicians\n\n* Clinician from participating clinic\n* At least 18 years of age\n* Can speak and understand English\n\nEligibility Criteria for Primary Care and Specialty Patients\n\nInclusion:\n\n* Patient at participating clinic\n* Age 18 years or older, inclusive\n* Current smoking (cigarettes per day \\>=5)\n* Can speak and understand English\n* Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline\n\nExclusion:\n\n* Active use of smoking cessation medication (within the past 30 days)\n* Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)\n* Having a contraindication for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)",{"count":603,"type":21},850,[55],"This study examines the application of precision treatment intervention for smoking cessation from both the clinician perspective and patient perspective, and compares it to usual care on tobacco treatment in the primary care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This approach may increase effectiveness and adherence for the patient, and increase the clinician's likelihood of prescribing.",[607,28,27],"Physician's Role",[609,610,611],"genetics","primary care physicians","tobacco treatment",{"date":566,"type":34},{"date":614,"type":34},"2023-09-29",{"date":616,"type":21},"2028-09-30",{"name":618,"class":41},"Washington University School of Medicine"]